Resistance management of Brigatinib/Brigatinib

Brigatinib/Brigatinib is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR).It can be used to treat non-small cell lung cancer (NSCLC). If the patient develops drug resistance during treatment, the following treatment methods can be considered. However, since each person's drug resistance response is different, the patient should inform the doctor in time.

1.Change the treatment plan: Depending on the patient's specific situation, you can consider changing to other drugs for treatment, such as changing to other tyrosine kinase inhibitor (TKI) drugs, or using other treatments in combination, such as chemotherapy, radiotherapy, etc.

2. Combination therapy: In the case of brigatinib resistance, other drugs can be considered for treatment, such as immune checkpoint inhibitors and other drugs, to improve the therapeutic effect.

3. Increase the dose: In some cases, increasing the dose of the drug can prolong the patient's survival, but attention needs to be paid to the control of the drug dose to avoid adverse reactions.

4. Adjust the medication time: Some studies have shown that adjusting the drug medication time can affect the metabolism and action of the drug. Therefore, in the case of brigatinib resistance, you can consider adjusting the medication time to improve the therapeutic effect.

This original drug is marketed in China under the name brigatinib, and has entered the scope of Class B medical insurance. Specifications The price of 30mg*14 tablets*2 tablets per box may be around 8,000 yuan, which is relatively expensive. Currently, there are relatively cheap generic brigatinib drugs on the market overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad. For example, the price of a box of 90mg*30 tablets produced by a Bangladesh pharmaceutical factory is around 2,000 yuan (the price may fluctuate due to exchange rates).